Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Most dividend yields ...

Once the golden child of the weight-loss boom, the Danish drugmaker now faces a painful financial slimming of its own.

Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...

This week, drugmakers had a scare when President Trump threatened to levy tariffs of up to 250% on imported pharmaceuticals.

Hims & Hers posted record revenue this quarter. It is still selling patented weight loss drugs on its platform and is now ...

Biocon Biologics Ltd, the biosimilars unit of biopharmaceutical giant Biocon and its largest revenue driver, expects to ...